CJC-1295 DAC vs No DAC: The Pulse-Amplitude Problem
The two versions of CJC-1295 share a name and almost nothing else — one mimics your natural growth-hormone rhythm, the other flattens it.
Abstract: CJC-1295 DAC vs no DAC is usually framed as a convenience trade-off — once-weekly versus daily injections. That framing misses the point. The real difference is the shape of the growth-hormone signal each one creates, and only one of them matches the pulsatile rhythm that aging actually erodes. This guide explains the pharmacology, the human evidence, and why mechanism-minded researchers treat these as two different compounds.
The single most common mistake in the growth-hormone-peptide world is treating “CJC-1295 DAC” and “CJC-1295 no DAC” as the same molecule at two dosing schedules. They are not. They produce fundamentally different patterns of growth hormone (GH) release, and that pattern — not the peak height or the injection frequency — is what determines whether you are working with your physiology or against it. If you want the broader decision map, start with how to choose a growth hormone peptide; this article zooms into the one fork that confuses the most buyers.
TL;DR: what DAC actually changes
“DAC” stands for Drug Affinity Complex — a maleimidopropionic acid group bolted onto the peptide that lets it bind covalently to albumin in your blood. That single addition is the entire difference:
- CJC-1295 with DAC binds albumin and circulates for 5.8–8.1 days (a true half-life, measured in healthy adults). One injection keeps GH and IGF-1 elevated for the better part of a week.
- CJC-1295 without DAC — properly called Modified GRF (1-29), or Mod GRF 1-29 — has no albumin anchor. Its half-life is roughly 20–50 minutes. It produces a sharp, short burst of GH and then clears.
A naming trap worth flagging immediately: in the published literature, “CJC-1295” means the DAC version. The short-acting one is technically Mod GRF 1-29, even though vendors sell it as “CJC-1295 no DAC.” Same backbone, opposite behaviour.
The GH axis is pulsatile — and aging steals amplitude, not baseline
To see why the DAC distinction matters, you have to understand how your body releases GH in the first place. Growth hormone is not secreted at a steady level. It comes out in pulses — roughly every two to three hours, with about 93% of daily GH released in those pulses and only ~7% as a low basal trickle. The largest pulse fires shortly after you fall asleep; in men it can account for 70–85% of the entire day’s output.
Here is the fact that reframes the whole debate: aging lowers the amplitude of those pulses, not their frequency and not the baseline. GH output falls roughly 1% per year after age 30 (a process called somatopause), and it does so by making each pulse smaller — not by raising or lowering the quiet troughs in between (Veldhuis 2012; Nass 2008).
So if the goal is to counter age-related decline, the physiologically sensible move is to restore pulse height while preserving the troughs. A short-acting GHRH analog does exactly that: it amplifies the natural pulse — by up to ~2.5× — and then lets GH fall back to baseline. That return to a low trough is not a bug. It is when the AMPK and sirtuin “repair and cleanup” pathways switch on, and when you step out of the mTOR/IGF-1 “growth” state.
CJC-1295 with DAC: what the human data actually show
The DAC version is the better-studied of the two, and the evidence is genuinely interesting — it just doesn’t say what the marketing implies.
In the landmark human trial, a single subcutaneous injection of CJC-1295 raised mean plasma GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for nine to eleven days; with repeated weekly or twice-weekly dosing, IGF-1 stayed above baseline for up to 28 days. It was safe and reasonably well tolerated at 30–60 mcg/kg (Teichman 2006, JCEM). In a GHRH-knockout mouse, once-daily CJC-1295 normalised growth (Alba 2006) — proof the molecule works as a GHRH agonist.
Now the nuance most comparison articles skip. A companion analysis found that pulsatile GH secretion persists even during continuous CJC-1295 stimulation (PMID 17018654). In other words, the DAC version does not abolish your pulses. What it does is raise the basal/trough GH roughly 7.5× so that the pulses now ride on top of a permanently elevated floor. You keep the waves, but the tide never goes out.
That is the problem in one sentence: aging is lost pulse amplitude, and the DAC version mostly raises the baseline — which is the one thing aging didn’t take from you.
CJC-1295 without DAC (Mod GRF 1-29): the pulsatile cousin
Mod GRF 1-29 is the short-acting form. Structurally it’s the first 29 amino acids of GHRH with four amino-acid substitutions that resist enzymatic breakdown and boost potency to roughly 4× that of sermorelin in rodent assays (Ionescu 2006). Because it clears in under an hour, it produces a clean spike-and-return that mimics a natural pulse — exactly the amplitude-restoring profile described above.
The honest catch: there are no human clinical studies on Mod GRF 1-29 itself. Its effects are inferred from its structural parents (sermorelin and tesamorelin) and from animal pharmacology. Everything about its real-world dosing comes from physician and bodybuilding anecdote, not trials — so treat any protocol as speculative. In practice it is the GHRH base most often stacked with ipamorelin, because a short-acting GHRH plus a selective GHRP produces a synergistic, still-pulsatile GH release. For a deeper build, see the dedicated Mod GRF 1-29 protocol guide.
The pulse-amplitude problem, stated plainly
Put the two side by side and the trade-off becomes a physiology question, not a convenience one:
| CJC-1295 with DAC | CJC-1295 no DAC (Mod GRF 1-29) | |
|---|---|---|
| Half-life | 5.8–8.1 days | ~20–50 min |
| Dosing | ~1–2 mg once weekly | ~100–300 mcg, 1–3×/day |
| GH pattern | Pulses on a raised floor (basal ~7.5×) | Sharp pulse → return to baseline |
| Matches aging deficit? | No — raises baseline, not amplitude | Yes — restores amplitude |
| Human evidence | Small phase-1 PK (Teichman 2006); no outcome trials | None on the compound itself |
| Longevity logic | Persistent GH/IGF-1 keeps you in growth (mTOR) mode | Troughs preserved → repair (AMPK/sirtuin) windows intact |
| Main appeal | Fewest injections | Physiologic signal shape |
The case against the DAC version for health-and-longevity goals isn’t that it doesn’t raise GH — it clearly does. It’s that never returning to a low trough may be exactly what you don’t want. Chronically elevated GH and IGF-1 keep growth-signalling pathways switched on continuously. Because IGF-1 feeds (though does not by itself cause) existing cancers — epidemiology associates each +38 ng/mL of IGF-1 with roughly an 8–18% higher risk across several common cancers — and because the IGF-1–to–mortality relationship appears U-shaped, “more GH, all the time” is a poor proxy for “healthier.” A signal that peaks and recedes is the more conservative choice. None of this is a verdict on any individual; it’s the mechanistic reasoning researchers use, and it is exactly the kind of trade-off covered in the broader peptide safety guide.
Safety notes that belong in the comparison
Two DAC-specific points deserve to be on the table. First, the original phase-2 trial of the DAC version (in HIV-associated lipodystrophy, ~120 participants) was terminated and never published after a participant death that an adjudication deemed unrelated and cardiac in nature. That doesn’t establish the drug as dangerous, but an unpublished, halted trial is a meaningful information gap. Second, the DAC version is more prone to fluid retention than the short-acting forms, a predictable consequence of sustained GH elevation.
The regulatory status of CJC-1295 has also been in flux — it was pulled from US compounding at one point and later reported re-allowed for prescription. Verify current status before assuming availability.
How mechanism-minded researchers choose
Framed as research-use-only reasoning, not medical advice:
- If the priority is matching natural physiology (the amplitude-restoration logic above), the short-acting CJC-1295 without DAC — ideally on a GHRH-base-plus-GHRP model — is the mechanistically coherent pick, with the loud caveat that it is unproven in humans.
- If the only goal is minimal injections and someone accepts the non-physiologic profile, CJC-1295 with DAC exists for that reason. Most researchers prioritising longevity take it off the table.
- If you want an actually-studied GHRH, sermorelin and tesamorelin both have human data and a pulsatile profile — frequently a better starting point than either CJC variant for someone new to the GH axis.
On sourcing: because these two products look identical on a label, demand a certificate of analysis (COA) that confirms which molecule you actually have — third-party identity and purity testing matter more here than almost anywhere else in the peptide space, precisely because the names are so easily swapped.
FAQ
Is CJC-1295 DAC stronger than no DAC? It produces a longer and higher baseline GH elevation, not a bigger pulse. “Stronger” depends on your goal: for sustained IGF-1, DAC does more; for a natural-shaped pulse, the no-DAC form is the better match.
Why do people say no-DAC is better for anti-aging? Because aging reduces GH pulse amplitude, not baseline. The short-acting form restores amplitude and lets GH fall back to a trough; the DAC form mainly raises the baseline and keeps you in a continuous growth-signalling state.
Can you stack CJC-1295 no DAC with ipamorelin? Yes — a short-acting GHRH base plus a selective GHRP like ipamorelin is the classic combination, and the two act synergistically while keeping release pulsatile. See the CJC-1295 + ipamorelin stack.
Is there human research on CJC-1295 no DAC? Not on the compound itself. The DAC version has small phase-1 pharmacokinetic data (Teichman 2006); Mod GRF 1-29’s effects are inferred from related GHRH analogs and animal work. Treat its protocols as speculative.
What does “DAC” actually mean? Drug Affinity Complex — a chemical group that binds the peptide to albumin in your blood, stretching its half-life from minutes to days.
References
- Teichman, S.L. et al. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab, 91(3), 799-805. doi:10.1210/jc.2005-1536
- Pulsatile secretion of GH persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (2006). PMID 17018654
- Alba, M. et al. (2006). Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab, 291(6), E1290-E1294.
- Ionescu, M. & Frohman, L.A. (2006). Modified GRF (1-29): a potent GHRH agonist. (Mod GRF 1-29 / CJC-1295 without DAC)
- Veldhuis, J.D. et al. (2012). Pulsatile Growth Hormone Secretion: Clinical Applications. Endocrine Reviews.
- Nass, R. et al. (2008). Growth Hormone Axis and Aging. Best Pract Res Clin Endocrinol Metab.
Research and educational use only. This article describes what has been reported in laboratory and clinical research and does not constitute medical advice, a treatment recommendation, or personalized dosing guidance. Peptides discussed are not approved for general human use except where noted. Consult a qualified clinician before making any health decision. — Indexa Labs Research Team